NCT05223478View on ClinicalTrials.gov

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

April 28, 2022

Conditions
MydriasisDilation
Interventions
DRUG

Phentolamine Ophthalmic Solution 0.75%

0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

DRUG

Phentolamine Ophthalmic Solution Vehicle

Phentolamine Ophthalmic Solution Vehicle

Trial Locations (2)

32779

Clinical Site 1, Longwood

45701

Clinical Site 2, Athens

Sponsors
All Listed Sponsors
lead

Ocuphire Pharma, Inc.

INDUSTRY

NCT05223478 - Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects | Biotech Hunter | Biotech Hunter